Latest Medical Imaging News

Cyclopharm Limited confirms its insurer has assumed responsibility for defending the company in ongoing legal proceedings initiated by 4DMedical Limited. This development marks a significant step in managing the dispute’s financial and operational risks.

Mach7 Technologies has been notified that the Veterans Health Administration will cease its NextGen PACS program, leading to a partial stop work order and cancellation of Phase 2 of the contract. Despite this, Mach7 remains focused on its broader commercial strategy.

Telix Pharmaceuticals has achieved a key milestone with China’s NMPA accepting its New Drug Application for Illuccix, a prostate cancer imaging agent backed by strong Phase 3 data. This paves the way for Telix to enter a rapidly growing Chinese market alongside its global approvals.

4DMedical Limited has raised AU$150 million to accelerate the commercial rollout of its FDA-cleared CT, VQ lung imaging technology in the US, leveraging a strategic partnership with Philips. This funding aims to expand adoption across major medical centres and government healthcare programs.

Cyclopharm secures a landmark deal with Lucile Packard Children’s Hospital Stanford to introduce Technegas, marking the first dedicated children’s hospital in the US to adopt this advanced lung imaging technology.

Imagion Biosystems has completed the conversion of its first tranche convertible notes with Mercer Street, issuing over 3 million shares, while renegotiating terms on the second tranche to extend maturity and reduce debt.

IRIS Metals has identified significant high-grade rubidium mineralisation at its Beecher Project in South Dakota, complementing its existing lithium resources and positioning the project as a leading multi-commodity critical minerals asset in the US.

Clarity Pharmaceuticals’ novel diagnostic agent Cu-SAR-bisPSMA has been selected for oral presentation at the prestigious European Association of Urology Congress 2026, following promising Phase II trial results demonstrating superior detection of prostate cancer recurrence.

Enlitic has locked in commitments for an A$8 million convertible note capital raise, with initial funds arriving immediately and the remainder pending shareholder approval. This funding aims to extend the company’s runway as it advances its AI-driven healthcare solutions.

Blue Star Helium Limited has raised up to A$8.2 million through a placement and rights issue to fund production scale-up and further drilling at its Galactica helium project in North America.

Cyclopharm Limited has secured regulatory approval for its Technegas lung imaging technology in Colombia, marking its presence in 67 countries worldwide. This milestone aligns strategically with the upcoming global nuclear medicine congress in Cartagena.

Micro-X Limited has secured $6 million through a share placement to accelerate commercialisation of its innovative medical imaging technologies, with strategic partner Billion Prima increasing its stake to 8.5%. The capital raise supports key clinical trials and product development milestones.